-Author name in bold denotes the presenting author
-Asterisk * with author name denotes a Non-ASH member
Clinically Relevant Abstract denotes an abstract that is clinically relevant.

PhD Trainee denotes that this is a recommended PHD Trainee Session.

Ticketed Session denotes that this is a ticketed session.

2024 Ham-Wasserman Lecture

Program: Marquee Sessions
Hematology Disease Topics & Pathways:
Sickle Cell Disease, Diversity, Equity, and Inclusion (DEI), Hemoglobinopathies, Diseases, Study Population
Saturday, December 7, 2024: 12:30 PM-1:30 PM
Hall B (San Diego Convention Center)
Chair:
Mohandas Narla, DSc, New York Blood Center
Disclosures:
No relevant conflicts of interest to declare.

Sickle cell disease (SCD) is an inherited red blood cell (RBC) disorder caused by either homozygous inheritance of the hemoglobin S mutation (HbSS), or compound heterozygous inheritance of the hemoglobin S mutation with another β-globin chain abnormality. India has among the highest hemoglobin S allele frequencies in the world and the third-highest birth rate for babies born with HbSS. 

The Indian sickle cell haplotype is associated with the Arab-Indian or Asian haplotype and is associated with high fetal hemoglobin (HbF) levels and hence, is believed to have mild clinical presentation as compared to other populations.  

 

In this lecture Dr. Dipty Jain will discuss the status of frequency, comorbidities, and management of sickle cell disease (SCD) in India, which is characterized by relatively high percentages of fetal hemoglobin, accompanied by mild to severe complications observed globally. Additionally she will talk about targeted newborn screening and fixed low dose of hydroxyurea in managing children with sickle cell disease in India. 

Dr. Jain will discuss the milestones and progress in understanding sickle cell disease (SCD) phenotype accelerated by the Government of India’s ambitious ‘’National Sickle Cell Anemia Elimination Mission 2023’’ with comprehensive guidelines and implementation of screening, treat, counsel, educate, development of technology and novel therapies including gene therapy specific to the requirement of India’s population with sickle cell disease (SCD). 

Dipty Lalit Jain, MD, MBBS

Pediatrics, Government Medical College and Hospital, Nagpur, NAGPUR, Maharastra, India; Arihant Multi-speciality hospital, Nagpur, India

See more of: Marquee Sessions